These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24682973)

  • 21. Immunological markers of optimal response to natalizumab in multiple sclerosis.
    Villar LM; García-Sánchez MI; Costa-Frossard L; Espiño M; Roldán E; Páramo D; Lucas M; Izquierdo G; Álvarez-Cermeño JC
    Arch Neurol; 2012 Feb; 69(2):191-7. PubMed ID: 22332187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.
    Mellergård J; Tisell A; Blystad I; Grönqvist A; Blennow K; Olsson B; Dahle C; Vrethem M; Lundberg P; Ernerudh J
    Eur J Neurol; 2017 Jan; 24(1):112-121. PubMed ID: 27699930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.
    Bhargava P; Wicken C; Smith MD; Strowd RE; Cortese I; Reich DS; Calabresi PA; Mowry EM
    Mult Scler Relat Disord; 2019 May; 30():136-140. PubMed ID: 30771580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers.
    Ottervald J; Franzén B; Nilsson K; Andersson LI; Khademi M; Eriksson B; Kjellström S; Marko-Varga G; Végvári A; Harris RA; Laurell T; Miliotis T; Matusevicius D; Salter H; Ferm M; Olsson T
    J Proteomics; 2010 Apr; 73(6):1117-32. PubMed ID: 20093204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
    Vennegoor A; Rispens T; Strijbis EM; Seewann A; Uitdehaag BM; Balk LJ; Barkhof F; Polman CH; Wolbink G; Killestein J
    Mult Scler; 2013 Apr; 19(5):593-600. PubMed ID: 22992450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defining active progressive multiple sclerosis.
    Sellebjerg F; Börnsen L; Ammitzbøll C; Nielsen JE; Vinther-Jensen T; Hjermind LE; von Essen M; Ratzer RL; Soelberg Sørensen P; Romme Christensen J
    Mult Scler; 2017 Nov; 23(13):1727-1735. PubMed ID: 28831853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natalizumab reduces serum pro-angiogenic activity in MS patients.
    Iaffaldano P; Ribatti D; Trojano M
    Neurol Sci; 2018 Apr; 39(4):725-731. PubMed ID: 29441483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
    J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis.
    Börnsen L; Khademi M; Olsson T; Sørensen PS; Sellebjerg F
    Mult Scler; 2011 Jan; 17(1):32-42. PubMed ID: 20921238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
    Harrer A; Tumani H; Niendorf S; Lauda F; Geis C; Weishaupt A; Kleinschnitz C; Rauer S; Kuhle J; Stangel M; Weber F; Uhr M; Linnebank M; Wildemann B; Jarius S; Guger M; Ayzenberg I; Chan A; Zettl U; Wiendl H; Pilz G; Hitzl W; Weber JR; Kraus J
    Mult Scler; 2013 Aug; 19(9):1209-12. PubMed ID: 23093485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF neurofilament light chain testing as an aid to determine treatment strategies in MS.
    Reyes S; Smets I; Holden D; Carrillo-Loza K; Christmas T; Bianchi L; Ammoscato F; Turner B; Marta M; Schmierer K; Giovannoni G; Gnanapavan S
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32826298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study.
    Borriello G; Prosperini L; Mancinelli C; Giannì C; Fubelli F; Pozzilli C
    Eur J Neurol; 2012 May; 19(5):783-7. PubMed ID: 22054236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis.
    Magliozzi R; Pitteri M; Ziccardi S; Pisani AI; Montibeller L; Marastoni D; Rossi S; Mazziotti V; Guandalini M; Dapor C; Schiavi G; Tamanti A; Nicholas R; Reynolds R; Calabrese M
    Ann Clin Transl Neurol; 2021 Mar; 8(3):534-547. PubMed ID: 33484486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.
    Tur C; Montalban X; Tintoré M; Nos C; Río J; Aymerich FX; Brieva L; Téllez N; Perkal H; Comabella M; Galán I; Calle D; Sastre-Garriga J; Rovira A
    Arch Neurol; 2011 Nov; 68(11):1421-7. PubMed ID: 22084124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
    Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
    Topping J; Dobson R; Lapin S; Maslyanskiy A; Kropshofer H; Leppert D; Giovannoni G; Evdoshenko E
    Mult Scler Relat Disord; 2016 Mar; 6():49-53. PubMed ID: 27063622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical predictors of an optimal response to natalizumab in multiple sclerosis.
    Sargento-Freitas J; Batista S; Macario C; Matias F; Sousa L
    J Clin Neurosci; 2013 May; 20(5):659-62. PubMed ID: 23485407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune cells after prolonged Natalizumab therapy: implications for effectiveness and safety.
    Marousi S; Karkanis I; Kalamatas T; Travasarou M; Paterakis G; Karageorgiou CE
    Acta Neurol Scand; 2013 Jul; 128(1):e1-5. PubMed ID: 23311457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.